Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line.
Durusu İZ et al. Leuk Res. 2017 Jan 16;55:33-40. doi: 10.1016/j.leukres.2017.01.019. [Epub ahead of print].

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.
Adamik J et al. Mol Cancer Res. 2017 Jan 23. pii: molcanres.0242.2016. doi: 10.1158/1541-7786.MCR-16-0242-T. [Epub ahead of print].

The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma.
Burwick N et al. Leuk Res. 2017 Jan 12;55:23-32. doi: 10.1016/j.leukres.2017.01.007. [Epub ahead of print].

CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model.
Imayoshi N et al. Biochem Biophys Res Commun. 2017 Jan 20. pii: S0006-291X(17)30138-9. doi: 10.1016/j.bbrc.2017.01.088. [Epub ahead of print].

Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.
Law PJ et al. Sci Rep. 2017 Jan 23;7:41071. doi: 10.1038/srep41071.

Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects.
Chen H et al. Mol Cancer Res. 2017 Jan 25. pii: molcanres.0293.2016. doi: 10.1158/1541-7786.MCR-16-0293. [Epub ahead of print].

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
Bar-Natan M et al. Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14493. [Epub ahead of print].

Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells.
Nanavati C et al. Pharm Res. 2017 Jan 18. doi: 10.1007/s11095-017-2095-5. [Epub ahead of print].

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Aird F et al. Elife. 2017 Jan 19;6. pii: e21253. doi: 10.7554/eLife.21253.

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Manni S et al. Oncotarget. 2017 Jan 14. doi: 10.18632/oncotarget.14654. [Epub ahead of print].

Functional role and therapeutic targeting of p21-associated kinase 4 (PAK4) in multiple myeloma.
Fulciniti M et al. Blood. 2017 Jan 17. pii: blood-2016-06-724831. doi: 10.1182/blood-2016-06-724831. [Epub ahead of print].

Activation of c-Abl kinase potentiates the anti-myeloma drug lenalidomide by promoting DDA1 recruitment to the CRL4 ubiquitin ligase.
Gao S et al. J Biol Chem. 2017 Jan 13. pii: jbc.M116.761551. doi: 10.1074/jbc.M116.761551. [Epub ahead of print].

NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase.
Gu Z et al. J Hematol Oncol. 2017 Jan 13;10(1):17. doi: 10.1186/s13045-017-0392-4.

Racial disparities in treatment use for multiple myeloma.
Fiala MA et al. Cancer. 2017 Jan 13. doi: 10.1002/cncr.30526. [Epub ahead of print].

The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma.
Trudel S et al. Front Immunol. 2016 Dec 27;7:625. doi: 10.3389/fimmu.2016.00625. eCollection 2016.

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.
Schönfeld K et al. J Hematol Oncol. 2017 Jan 11;10(1):13. doi: 10.1186/s13045-016-0380-0.

An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
Passey C et al. AAPS J. 2017 Jan 9. doi: 10.1208/s12248-016-0033-9. [Epub ahead of print].

mTORC1 Plays an Important Role in Skeletal Development by Controlling pre-Osteoblast Differentiation.
Fitter S et al. Mol Cell Biol. 2017 Jan 9. pii: MCB.00668-16. doi: 10.1128/MCB.00668-16. [Epub ahead of print].

The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
Oliva L et al. Blood. 2017 Jan 27. pii: blood-2016-08-730978. doi: 10.1182/blood-2016-08-730978. [Epub ahead of print].

IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.
Bolzoni M et al. Haematologica. 2017 Jan 5. pii: haematol.2016.153841. doi: 10.3324/haematol.2016.153841. [Epub ahead of print].

PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells.
Li M et al. Exp Biol Med (Maywood). 2017 Jan 1:1535370216685008. doi: 10.1177/1535370216685008. [Epub ahead of print].

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L et al. Blood. 2017 Jan 4. pii: blood-2016-09-737536. doi: 10.1182/blood-2016-09-737536. [Epub ahead of print].

The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma.
Giuliani N et al. Expert Opin Ther Targets. 2017 Jan 18:1-4. doi: 10.1080/14728222.2017.1279148. [Epub ahead of print].

Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa.
Marcussen M et al. PLoS One. 2017 Jan 4;12(1):e0169286. doi: 10.1371/journal.pone.0169286. eCollection 2017.

Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
Baek YY et al. Oncotarget. 2016 Dec 28. doi: 10.18632/oncotarget.14343. [Epub ahead of print].

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M et al. Oncotarget. 2016 Dec 30. doi: 10.18632/oncotarget.14378. [Epub ahead of print].

Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy.
Imai T et al. Cancer Biol Ther. 2017 Jan 3:1-5. doi: 10.1080/15384047.2016.1276137. [Epub ahead of print].

Histone deacetylase inhibitors in plasma cell leukemia treatment: Effect of bone marrow microenvironment.
Burianova I, et al. Neoplasma. 2017 Jan 3;64(2). doi: 10.4149/neo_2017_209. [Epub ahead of print].

Population pharmacokinetics of lenalidomide in multiple myeloma patients.
Guglieri-López B et al. Cancer Chemother Pharmacol. 2017 Jan;79(1):189-200. doi: 10.1007/s00280-016-3228-y. Epub 2016 Dec 30.

Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.
Zatula A et al. Oncotarget. 2016 Dec 27. doi: 10.18632/oncotarget.14294. [Epub ahead of print].

Histone deacetylases meet microRNA-associated MMP-9 expression regulation in glucocorticoid-sensitive and -resistant cell lines.
Hentati-Kallel M et al. Int J Oncol. 2017 Feb;50(2):717-726. doi: 10.3892/ijo.2016.3830. Epub 2016 Dec 30.

Aggregation of Full Length Immunoglobulin Light Chains from AL Amyloidosis Patients Is Remodeled by Epigallocatechin-3-gallate.
Andrich K et al. J Biol Chem. 2016 Dec 28. pii: jbc.M116.750323. doi: 10.1074/jbc.M116.750323. [Epub ahead of print].

Evolutionary Dynamics of Tumor-Stroma Interactions in Multiple Myeloma.
Sartakhti JS et al. PLoS One. 2016 Dec 28;11(12):e0168856. doi: 10.1371/journal.pone.0168856.

Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.
Tsvetkov P et al. Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):382-387. doi: 10.1073/pnas.1619067114. Epub 2016 Dec 27.

Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins.
van Andel H et al. Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):376-381. doi: 10.1073/pnas.1618650114. Epub 2016 Dec 27.

Multiple myeloma cells capacity to decompose H2O2 determines lenalidomide sensitivity.
Sebastian S et al. Blood. 2016 Dec 27. pii: blood-2016-09-738872. doi: 10.1182/blood-2016-09-738872. [Epub ahead of print].

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
Hipp S et al. Leukemia. 2017 Jan 13. doi: 10.1038/leu.2016.388. [Epub ahead of print].